Novo Nordisk invests an additional $100 million to expand its research facilities in Beijing, China. The new 12,000-m2 center will make an increase from 130 to 200 science employees possible, with extra space available to accommodate additional future growth.
Novo Nordisk was the first multinational company to open a research center in China in 1997. The site in Beijing has already contributed significantly to the company’s research and development portfolio in both diabetes and biopharmaceutical target disease areas. The new, expanded facility will enable even stronger contributions from the science team in China across the range of Novo Nordisk’s protein technology, biology and pharmacology research activities.
- Novo Nordisk A/S, Bagsværd, Denmark